Dyne Therapeutics Files 8-K for Regulatory Updates
Ticker: DYN · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Dyne Therapeutics filed a routine 8-K on 6/17/25 for disclosures.
AI Summary
Dyne Therapeutics, Inc. filed an 8-K on June 17, 2025, to report on other events and provide financial statements and exhibits. The filing does not detail specific transactions or financial results but serves as a general update and repository for required documentation.
Why It Matters
This filing indicates Dyne Therapeutics is meeting its regulatory disclosure obligations, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard regulatory filing with no new material information disclosed.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of report
- 1560 Trapelo Road Waltham, Massachusetts 02451 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Dyne Therapeutics, Inc.?
The primary purpose is to report on 'Other Events' and to provide 'Financial Statements and Exhibits' as of June 17, 2025.
What is the filing date for this 8-K?
The filing date is June 17, 2025.
What is Dyne Therapeutics, Inc.'s principal executive office address?
The principal executive office is located at 1560 Trapelo Road, Waltham, Massachusetts 02451.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Does this 8-K filing disclose any specific new material events or financial results?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' but does not detail specific new material events or financial results within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Dyne Therapeutics, Inc. (DYN).